CN108524731B - Traditional Chinese medicine composition for treating myasthenia gravis and preparation thereof - Google Patents
Traditional Chinese medicine composition for treating myasthenia gravis and preparation thereof Download PDFInfo
- Publication number
- CN108524731B CN108524731B CN201810769797.XA CN201810769797A CN108524731B CN 108524731 B CN108524731 B CN 108524731B CN 201810769797 A CN201810769797 A CN 201810769797A CN 108524731 B CN108524731 B CN 108524731B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- myasthenia gravis
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 76
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 206010028417 myasthenia gravis Diseases 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 210000003038 endothelium Anatomy 0.000 claims abstract description 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 8
- 210000000952 spleen Anatomy 0.000 claims description 33
- 210000002784 stomach Anatomy 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 10
- 239000006187 pill Substances 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- 244000189799 Asimina triloba Species 0.000 claims description 9
- 235000006264 Asimina triloba Nutrition 0.000 claims description 9
- 241000045403 Astragalus propinquus Species 0.000 claims description 9
- 235000009467 Carica papaya Nutrition 0.000 claims description 9
- 244000183685 Citrus aurantium Species 0.000 claims description 9
- 235000007716 Citrus aurantium Nutrition 0.000 claims description 9
- 241000096284 Gynochthodes officinalis Species 0.000 claims description 9
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 9
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 9
- 235000006533 astragalus Nutrition 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 241000382455 Angelica sinensis Species 0.000 claims description 8
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 8
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 8
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 8
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 8
- 244000197580 Poria cocos Species 0.000 claims description 8
- 235000008599 Poria cocos Nutrition 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 241000132012 Atractylodes Species 0.000 claims description 7
- 241000007126 Codonopsis pilosula Species 0.000 claims description 7
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 7
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 7
- 244000182216 Mimusops elengi Species 0.000 claims description 7
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 7
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 7
- 235000011477 liquorice Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 5
- 230000009466 transformation Effects 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 5
- 241000756943 Codonopsis Species 0.000 abstract description 3
- 206010028372 Muscular weakness Diseases 0.000 abstract description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 abstract description 2
- 229940104299 cimicifugae rhizoma Drugs 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 230000000857 drug effect Effects 0.000 abstract description 2
- 239000009636 Huang Qi Substances 0.000 abstract 1
- 239000010135 fructus aurantii immaturus Substances 0.000 abstract 1
- 230000036473 myasthenia Effects 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 description 16
- 230000007812 deficiency Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- 239000008280 blood Substances 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 239000008107 starch Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 235000015961 tonic Nutrition 0.000 description 9
- 230000001256 tonic effect Effects 0.000 description 9
- 229960000716 tonics Drugs 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 235000008216 herbs Nutrition 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 210000002435 tendon Anatomy 0.000 description 7
- 229920001353 Dextrin Polymers 0.000 description 6
- 239000004375 Dextrin Substances 0.000 description 6
- 235000019425 dextrin Nutrition 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 238000010298 pulverizing process Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 235000012907 honey Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 208000019505 Deglutition disease Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000019605 sweet taste sensations Nutrition 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 241000906543 Actaea racemosa Species 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 241000213015 Bupleurum scorzonerifolium Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000077995 Coix lacryma jobi Species 0.000 description 2
- 241000220485 Fabaceae Species 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241001093501 Rutaceae Species 0.000 description 2
- 208000031975 Yang Deficiency Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 235000005301 cimicifuga racemosa Nutrition 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000027140 splenic disease Diseases 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 241000905376 Actaea dahurica Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000092665 Atractylodes macrocephala Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 1
- 235000016646 Citrus taiwanica Nutrition 0.000 description 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 241000234272 Dioscoreaceae Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000019229 Spleen disease Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003866 digestant Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- -1 drying Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000026591 functional gastric disease Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940125698 hormone suppressant Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 201000010727 rectal prolapse Diseases 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating myasthenia gravis and a preparation thereof, wherein the traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials: radix Morindae officinalis, Saviae Miltiorrhizae radix, fructus Aurantii Immaturus, radix Codonopsis, radix astragali, bupleuri radix, Atractylodis rhizoma, radix Angelicae sinensis, cimicifugae rhizoma, Glycyrrhrizae radix, pericarpium Citri Tangerinae, fructus Lycii, rhizoma Dioscoreae, endothelium corneum Gigeriae Galli, fructus Chaenomelis, and Poria; the invention also discloses a pharmaceutical preparation and a dosage form for treating myasthenia gravis, wherein the pharmaceutical preparation consists of a traditional Chinese medicine composition and corresponding conventional pharmaceutical excipients. The traditional Chinese medicine composition disclosed by the invention is reasonable in formula and scientific in proportioning, achieves optimal drug effect synergy, and has a better treatment effect on severe myasthenia.
Description
Technical Field
The invention relates to the field of biological medicines, and relates to a traditional Chinese medicine composition for treating myasthenia gravis and a preparation thereof.
Background
Myasthenia Gravis (MG) is an autoimmune disease that mainly involves the receptor for acetylcholine (AchR) on the postsynaptic membrane of the neuromuscular junction. The clinical manifestations are partial or whole body skeletal muscle weakness and fatigue, aggravation of symptoms after activity, and alleviation of symptoms after rest and treatment with cholinesterase inhibitors (ChEI). The pathogenesis of this disease has not been completely elucidated to date.
The traditional Chinese medicine is mainly discussed in the aspects of spleen and stomach deficiency, spleen and kidney yang deficiency, liver and kidney yin deficiency, meridian deficiency and the like. The theory of spleen-stomach deficiency considers that the pathogenesis of MG is of spleen-stomach deficiency type. Because the spleen is the ' acquired root ' and the stomach is the ' sea of food, the spleen can transform food into essence and can irrigate the periphery to enrich the five internal organs, and the spleen and the stomach can transport and transport the essence and are closely matched. Dysfunction or disorder of spleen and stomach function, poor middle energizer and yang-qi and blood failing to nourish the extremities, and the muscles of the extremities cannot warm up, resulting in listlessness of the extremities.
The theory of yang deficiency of both spleen and kidney suggests that the physiological function of spleen depends on the promotion of kidney qi and kidney yin and kidney yang, and that essence stored in kidney depends on the moistening and cultivation of spleen, which mutually support and work. Both of them are mutually damaged, and the deficiency of both spleen and kidney, kidney essence deficiency, deficiency of both qi and blood, fatigue, weakness and hypofunction of the whole body, and atrophy-flaccidity syndrome.
The syndrome of liver-kidney yin deficiency is characterized by "blood sea", liver-blood deficiency, blood failing to nourish the muscles and tendons, flaccidity and indulgence of the tendons, liver-blood deficiency leading to liver-yang hyperactivity, yang hyperactivity transforming wind, liver-wind carrying phlegm stagnation in the tendons and vessels, and atrophy and disability of the limbs.
The speakers of deficient impairment of meridians think that the extra meridians and collaterals are deficient and damaged and the meridians and collaterals are deficient and stagnated, the extra meridians and the eight meridians run up and down and are distributed throughout the whole body, and the eight extra meridians are governing yin and yang, infiltrating and irrigating three yin and three yang, crossing twelve meridians, connecting the twelve meridians and the internal organs, and infiltrating and irrigating the twelve regular meridians if the extra meridians and the eight extra meridians are vigorous in qi and blood; the deficient impairment of meridians and collaterals, loss of nourishment of tendons and muscles, which leads to this disease.
Research on MG treatment by the traditional Chinese medicine has become a hotspot in the field of traditional Chinese medicine, wherein a spleen-tonifying and kidney-tonifying method for treating MD has a certain proportion, and a large number of clinical researches prove that the MD has unique advantages in the aspects of improving symptoms, reducing adverse reactions of hormones and immunosuppressants, reducing the recurrence rate, improving the life quality of patients and the like, but at present, a traditional Chinese medicine preparation for effectively treating myasthenia gravis is still needed clinically to cure the myasthenia gravis patients, and a theoretical basis is provided for deeply researching the action mechanism of the spleen-tonifying and kidney-tonifying method for treating the spleen-kidney deficiency type MG patients.
Disclosure of Invention
In order to make up for the defects of the prior art, one of the purposes of the invention is to provide a traditional Chinese medicine composition for treating myasthenia gravis.
The invention also aims to provide a pharmaceutical preparation for treating myasthenia gravis.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention provides a traditional Chinese medicine composition for treating myasthenia gravis, which is prepared from the following traditional Chinese medicine raw materials in parts by weight: 8-15 parts of morinda officinalis, 10-24 parts of salvia miltiorrhiza, 5-10 parts of immature bitter orange, 20-60 parts of codonopsis pilosula, 20-160 parts of astragalus membranaceus, 8-10 parts of radix bupleuri, 8-30 parts of bighead atractylodes rhizome, 8-15 parts of angelica sinensis, 8-10 parts of rhizoma cimicifugae, 3-6 parts of liquorice, 3-10 parts of pericarpium citri reticulatae, 6-15 parts of medlar, 12-30 parts of Chinese yam, 12-30 parts of endothelium corneum gigeriae galli, 6-15 parts of pawpaw and 15-30 parts of poria cocos.
Preferably, the traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 12 parts of morinda officinalis, 15 parts of salvia miltiorrhiza, 7 parts of immature bitter orange, 40 parts of codonopsis pilosula, 85 parts of astragalus membranaceus, 9 parts of radix bupleuri, 20 parts of bighead atractylodes rhizome, 12 parts of angelica sinensis, 9 parts of rhizoma cimicifugae, 5 parts of liquorice, 5 parts of pericarpium citri reticulatae, 10 parts of medlar, 25 parts of Chinese yam, 25 parts of endothelium corneum gigeriae galli, 12 parts of pawpaw and 20 parts of poria cocos.
The weight of the raw material medicines of the composition is calculated by crude medicines, and the raw material medicines are used as the proportion by weight, so that the raw material medicines can be increased or reduced in proportion during production, but the proportion of the raw material medicines in the weight proportion among the components is unchanged. The proportion of the weight proportion is obtained by scientific screening, the proportion of the components can be correspondingly adjusted, the increase or decrease is not more than 100%, and the drug effect is not changed.
In a second aspect, the present invention provides a pharmaceutical formulation comprising the Chinese medicinal composition of the first aspect of the present invention; or comprises the traditional Chinese medicine composition of the first aspect of the invention and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers include, but are not limited to, fillers, binders, wetting agents, disintegrants, absorption enhancers, surfactants, adsorptive carriers, or lubricants.
According to the invention, the filler is understood to be an excipient diluent to increase the weight and volume of the tablet to facilitate tabletting; or it should be understood that the adjunct absorbent is intended to absorb excess liquid components of the feed. In the present invention, the filler is, for example, starch, sucrose, lactose, microcrystalline cellulose, or the like.
The binder is understood to mean a substance to which a viscous substance called a binder is added for granulation when the raw material drug itself is not viscous or insufficiently viscous. The binder is, for example, cellulose derivatives, alginates, gelatin, polyvinylpyrrolidone, and the like.
The wetting agent is understood to be a liquid which is not sticky to the medicament itself, but which wets the pharmaceutical raw materials and induces stickiness and granulation. The wetting agent is, for example, glycerol or the like.
By disintegrant is understood an excipient which can be added to a tablet to facilitate its rapid disintegration into fine particles in the gastrointestinal fluids. It is known that tablets have a high hardness after compression, and if they contain no auxiliary material which promotes disintegration, they disintegrate slowly in the gastrointestinal tract, affecting the therapeutic effect. The disintegrating agent is, for example, sodium carboxymethyl starch, hydroxypropyl cellulose, cross-linked carboxymethyl cellulose, agar, calcium carbonate, sodium bicarbonate, etc. The absorption enhancer is, for example, a quaternary ammonium compound.
The absorption enhancer is understood to be a substance which serves to increase the bioavailability of the pharmaceutical preparation. The absorption enhancer is, for example, a quaternary ammonium compound.
The surfactant is, for example, cetyl alcohol, sodium lauryl sulfate, etc.; the adsorption carrier is, for example, kaolin, bentonite, etc.
The lubricant is understood to be a chemical substance that facilitates improved tablet flow during granulation, prevents tablet material from sticking to the tablet machine die, and facilitates tablet demolding. The lubricant is, for example, talc, calcium and magnesium stearate, colloidal silica, polyethylene glycol, and the like.
Other adjuvants are, for example, flavoring agents, sweeteners, etc.
Preferably, the pharmaceutical preparation is an oral, topical, or injectable preparation.
Preferably, the oral dosage form is selected from water extract, oral liquid, tablets, pills, powder, granules, capsules, dripping pills or health-care tea oral preparation. The selection of appropriate excipients and formulation methods according to the dosage form needs is a routine technique within the skill of the art.
The third aspect of the present invention provides a preparation method of the traditional Chinese medicine composition of the first aspect of the present invention, the preparation method comprises the steps of:
weighing the traditional Chinese medicine raw materials according to the prescription amount, crushing, grinding, sieving, adding water, decocting for 2 times, mixing decoction liquids to obtain a decoction liquid, concentrating, precipitating, filtering, drying to obtain an extract, and crushing into powder.
A fourth aspect of the invention provides a use as claimed in any one of:
a. the application of the traditional Chinese medicine composition in preparing the medicine for treating myasthenia gravis is disclosed in the first aspect of the invention;
b. use of a pharmaceutical formulation according to the second aspect of the invention in the manufacture of a medicament for the treatment of myasthenia gravis.
Preferably, the myasthenia gravis in a is myasthenia gravis accompanied by poor transportation and transformation of the spleen and stomach, yellow and greasy tongue coating and dysphagia.
Preferably, the myasthenia gravis in b is myasthenia gravis accompanied by poor transportation and transformation of the spleen and stomach, yellow and greasy tongue coating and dysphagia.
The traditional Chinese medicine composition for treating myasthenia gravis is scientific and reasonable in formula, and the effects and the functions of the raw material medicines are as follows:
astragalus root, the root of Astragalus mongholicus (Fisch.) bge and Astragalus membranaceus (Fisch.) bge of Leguminosae, is slightly warm in nature and sweet in flavor, and enters spleen and lung meridians. Invigorating qi, consolidating superficial resistance, promoting urination, expelling toxin, expelling pus, and promoting granulation. They belong to the category of qi tonics under deficiency-tonifying herbs.
Radix Codonopsis is derived from root of radix Codonopsis belonging to family Campanulaceae. Sweet and mild in nature and taste, can be used for treating diseases of hand and foot due to the qi system of the channel, tonifying middle-jiao, replenishing qi and promoting the production of body fluid. It is indicated for weakness of spleen and stomach, deficiency of both qi and blood, lassitude, weakness, poor appetite, thirst, chronic diarrhea, and rectocele.
Atractylodis rhizoma is dried rhizome of Atractylodes macrocephala Koidz of Compositae. Sweet and bitter in taste, warm in nature, entering spleen and stomach meridians, and used for spleen deficiency, anorexia, abdominal distention, diarrhea, phlegm and fluid retention, dizziness, palpitation, edema, spontaneous perspiration, threatened abortion.
Bupleuri radix is dried root of Bupleurum scorzonerifolium or Bupleurum scorzonerifolium of Umbelliferae, and is pungent, bitter and slightly cold in nature. It enters liver, gallbladder and lung meridians and has the actions of harmonizing exterior and interior, soothing liver and raising yang.
Cimicifugae rhizoma, which is dried rhizome of Cimicifuga racemosa, Cimicifuga dahurica or Cimicifuga racemosa of Ranunculaceae. Releasing exterior and promoting eruption, clearing heat and removing toxicity, and lifting yang qi. Pungent, slightly sweet and slightly cold, enter lung, spleen, stomach and large intestine meridians. Can be used for treating headache due to wind-heat evil, toothache, aphtha, sore throat, measles without adequate eruption, and macula due to yang toxin; prolapse of the anus and uterine prolapse.
Dang Gui is the root of Angelica sinensis of Umbelliferae, warm in nature, sweet and pungent in flavor. It enters liver meridian, heart meridian and spleen meridian. Tonify blood, activate blood, regulate menstruation, alleviate pain, moisten intestines and relieve constipation. They belong to the category of tonics.
Glycyrrhrizae radix, dried root and rhizome of Glycyrrhiza uralensis Fisch, Glycyrrhiza inflata Bat or Glycyrrhiza glabra L of Leguminosae, has mild nature and sweet taste. They enter heart, stomach, spleen and lung meridians. Invigorating spleen and replenishing qi, relieving cough and eliminating phlegm, relieving spasm and relieving pain, and harmonizing drug property. They belong to qi tonics classified under deficiency tonics.
Pericarpium Citri Tangerinae, mature pericarp of Rutaceae plant fructus Citri Tangerinae and its cultivar, pungent, bitter and warm in nature. It enters spleen and lung meridians. Regulate qi-flowing for promoting appetite, dry dampness and resolve phlegm, treat spleen and stomach diseases. Belongs to qi-regulating herbs.
Lycium barbarum, a mature fruit of Lycium barbarum L.of Solanaceae, has mild nature and sweet taste, and enters liver and kidney meridians. Nourishing liver and kidney, replenishing vital essence and improving eyesight. They belong to the yin tonics classified under the deficiency tonics.
Morinda officinalis, dried root of Morinda officinalis of Rubiaceae, slightly warm in nature, sweet and pungent in flavor. It enters kidney and liver meridians. Tonify kidney yang, strengthen tendons and bones, dispel wind-damp. They belong to yang tonics classified under deficiency tonics.
Yam, a rhizome of Dioscorea opposita Thunb of Dioscoreaceae, is neutral in nature and sweet in taste. It enters spleen, lung and kidney meridians. Invigorating spleen and stomach, promoting fluid production, benefiting lung, invigorating kidney, and arresting seminal emission. They belong to the category of qi tonics under deficiency-tonifying herbs.
Endothelium corneum Gigeriae Galli is the inner wall of dry ballast of domestic chicken of Phasianidae, and has mild nature and sweet taste. It enters spleen meridian, stomach meridian, small intestine meridian and bladder meridian. Strengthening the stomach, promoting digestion, arresting seminal emission and stopping enuresis. Belongs to the category of digestant drugs.
Pawpaw is a nearly mature fruit of pawpaw belonging to the family Rosaceae, and has warm nature and sour taste. It enters liver and spleen meridians. Pacify liver, relax tendons, harmonize stomach and resolve dampness. Belongs to the category of antirheumatic and tendon and bone strengthening drugs under the antirheumatic drugs.
Salvia miltiorrhiza, root and rhizome of Salvia miltiorrhiza, a plant of Labiatae, is slightly cold in nature and bitter in taste. It enters heart and liver meridians. Removing blood stasis, relieving pain, promoting blood circulation, relieving dysmenorrhea, clearing away heart-fire, and relieving restlessness. Belongs to the blood-activating and menstruation-regulating herbs classified under the blood-activating and stasis-resolving herbs.
Immature bitter orange, the young fruit of Citrus aurantium of Rutaceae, is slightly cold in nature, bitter, pungent and sour in flavor, and enters spleen and stomach meridians. Break qi and remove food retention, resolve phlegm and disperse distention and fullness. Belongs to qi-regulating herbs.
Poria, sclerotium of Poria cocos (Schw.) wolf of Polyporaceae, has mild nature and sweet and light taste. They enter heart, lung, spleen and kidney meridians. Induce diuresis and drain dampness, invigorate spleen and calm heart. Belongs to the diuresis-inducing and edema-alleviating herbs classified under the diuresis-inducing and dampness-excreting herbs.
Coix seed, mature seed of Coix lacryma-jobi of Gramineae. Cool in nature, sweet and bland in flavor. It enters spleen, stomach and lung meridians. Invigorating spleen, removing dampness, relieving arthralgia, relieving diarrhea, clearing away heat, and expelling pus. Belongs to the diuresis and stranguria treatment drugs classified under the diuresis and dampness eliminating drugs.
The invention has the advantages and beneficial effects that:
the traditional Chinese medicine composition for treating myasthenia gravis provided by the invention is scientific and reasonable in formula, various components are cooperatively compatible, the medicine effect can be quickly exerted, the composition is safe, free of toxic and side effects, low in cost, convenient for patients to take, simple to prepare and suitable for industrial production.
Detailed Description
The present invention will be described in further detail with reference to examples. The following examples are intended to illustrate the invention only and are not intended to limit the scope of the invention. The experimental methods in the examples, in which specific conditions are not specified, are generally carried out under conventional conditions. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be within the scope of the invention.
The traditional Chinese medicine composition and the pharmaceutical preparation are prepared by scientific formula screening on the premise of applying the theoretical basis of traditional Chinese medicine and refining and processing on the premise of applying the scientific extraction process of traditional Chinese medicines.
EXAMPLE 1 preparation of the Chinese medicinal composition
1. Accurately weighing the following traditional Chinese medicine raw materials in parts by weight: 8 parts of morinda officinalis, 10 parts of salvia miltiorrhiza, 5 parts of immature bitter orange, 20 parts of codonopsis pilosula, 20 parts of astragalus membranaceus, 8 parts of radix bupleuri, 8 parts of bighead atractylodes rhizome, 8 parts of angelica sinensis, 8 parts of rhizoma cimicifugae, 3 parts of liquorice, 3 parts of pericarpium citri reticulatae, 6 parts of medlar, 12 parts of Chinese yam, 12 parts of endothelium corneum gigeriae galli, 6 parts of pawpaw and 15 parts of poria cocos.
2. Pulverizing the above Chinese medicinal materials, and mixing.
EXAMPLE 2 preparation of the Chinese medicinal composition
1. Accurately weighing the following traditional Chinese medicine raw materials in parts by weight: 15 parts of morinda officinalis, 24 parts of salvia miltiorrhiza, 10 parts of immature bitter orange, 60 parts of codonopsis pilosula, 160 parts of astragalus membranaceus, 10 parts of radix bupleuri, 30 parts of bighead atractylodes rhizome, 15 parts of angelica sinensis, 10 parts of rhizoma cimicifugae, 6 parts of liquorice, 10 parts of pericarpium citri reticulatae, 15 parts of medlar, 30 parts of Chinese yam, 30 parts of endothelium corneum gigeriae galli, 15 parts of pawpaw and 30 parts of poria cocos.
2. Pulverizing the above Chinese medicinal materials, grinding, sieving to obtain fine powder, decocting in water for 2 times, mixing decoctions, concentrating, precipitating, filtering, drying to obtain extract, and pulverizing into powder.
EXAMPLE 3 preparation of the Chinese medicinal composition
1. Accurately weighing the following traditional Chinese medicine raw materials in parts by weight: 12 parts of morinda officinalis, 15 parts of salvia miltiorrhiza, 7 parts of immature bitter orange, 40 parts of codonopsis pilosula, 85 parts of astragalus membranaceus, 9 parts of radix bupleuri, 20 parts of bighead atractylodes rhizome, 12 parts of angelica sinensis, 9 parts of rhizoma cimicifugae, 5 parts of liquorice, 5 parts of pericarpium citri reticulatae, 10 parts of medlar, 25 parts of Chinese yam, 25 parts of endothelium corneum gigeriae galli, 12 parts of pawpaw and 20 parts of poria cocos.
2. Pulverizing the above Chinese medicinal materials, grinding, sieving to obtain fine powder, stirring, reflux-extracting with 5-10 times of 80% ethanol for 2 times (each for 1-2 hr), filtering, mixing reflux solutions, concentrating to obtain fluid extract, decocting in water for 2 times, mixing decoctions, concentrating to obtain fluid extract, dissolving in 5-6 times of water, loading onto macroporous resin column, sequentially eluting with water and 40% ethanol, recovering ethanol eluate, further concentrating to obtain soft extract, and pulverizing into powder.
EXAMPLE 4 preparation of Chinese medicinal preparation
1. Tablet formulation
Taking the traditional Chinese medicine composition in the embodiment 1-3, adding dextrin, starch and magnesium stearate, wherein the mass ratio of the dextrin, the starch and the magnesium stearate to the extract of the traditional Chinese medicine composition is 0.3-0.8: 0.6-1: 0.1-0.7: 1, uniformly mixing, granulating, drying, tabletting and coating to obtain the traditional Chinese medicine tablet.
2. Capsule preparation
Taking the traditional Chinese medicine composition in the embodiment 1-3, adding dextrin, starch and aerosil, wherein the mass ratio of the dextrin, the starch and the aerosil to the extract of the traditional Chinese medicine composition is 0.2-0.6: 0.6-0.8: 0.2-0.6: 1, uniformly mixing, granulating, drying, and encapsulating to obtain the traditional Chinese medicine capsule.
3. Granules
Taking the traditional Chinese medicine composition in the embodiment 1-3, adding dextrin, starch and microcrystalline cellulose, wherein the mass ratio of the dextrin, the starch and the microcrystalline cellulose to the extract of the traditional Chinese medicine composition is 0.2-0.4: 0.4-0.5: 0.4-0.6: 1, uniformly mixing, granulating, drying and subpackaging to obtain the traditional Chinese medicine granule.
4. Oral liquid
Taking the traditional Chinese medicine composition in the embodiment 1-3, adding distilled water until the mass ratio of the distilled water to the extract of the traditional Chinese medicine composition is 0.4-0.8: 1, uniformly stirring, adding sucrose, refined honey, methyl hydroxybenzoate and ethylparaben, wherein the mass ratio of the sucrose, the refined honey, the methyl hydroxybenzoate and the ethylparaben to the extract of the traditional Chinese medicine composition is 0.2-0.3: 0.1-0.2: 0.01-0.1: 1, uniformly stirring, filtering, encapsulating, sterilizing and packaging to obtain the traditional Chinese medicine oral liquid.
5. Pill preparation
Taking the traditional Chinese medicine composition in the embodiment 1-3, adding starch and refined honey, wherein the mass ratio of the starch to the refined honey to the extract of the traditional Chinese medicine composition is 0.6-1.5: 1.4-1.5: 1, placing in a sugar coating pan, rotating a sugar coating machine, adding 70% ethanol, stirring, forming pills, drying, coating, and packaging to obtain the traditional Chinese medicine pills.
6. Drop pills
Adding pharmaceutic adjuvants of polyethylene glycol 2000, polyethylene glycol 4000 and cosolvent polyethylene glycol 6000 into the traditional Chinese medicine composition of examples 1-3, wherein the mass ratio of the polyethylene glycol 2000, the polyethylene glycol 4000 and the polyethylene glycol 6000 to the extract of the traditional Chinese medicine composition is 0.2-0.6: 0.4-0.8: 0.4-0.6: 1, uniformly mixing, heating and melting, uniformly stirring, transferring the molten mixed liquid into a dripping pill machine for dripping, wherein the dripping temperature is 70 ℃, the diameter of a dripping head is 2.5cm, a condensing agent is dimethyl silicone oil, and the condensing temperature is 0 ℃; dripping at a speed of 60 drops/min and a distance of 5.5cm, taking out the dripping pill from the outlet of the dripping pill machine, removing surface condensing agent, drying, and packaging to obtain the final product.
EXAMPLE 5 therapeutic Effect of the Chinese medicinal composition
1. Preparation of Experimental drugs
An oral liquid was prepared according to the method of example 4
2. Test population (inclusion criteria):
54 patients with myasthenia gravis with poor transportation and transformation of the spleen and stomach, yellow and greasy tongue coating and dysphagia were collected and divided into three groups, and the three groups were treated with the traditional Chinese medicine composition described in examples 1-3.
3. The evaluation standard of curative effect is as follows:
the clinical symptoms of healing completely disappear; the relapse is not seen after the medicine is stopped for two months.
The improvement of clinical symptoms is obviously relieved;
no significant improvement or worsening of ineffective clinical symptoms.
4. The curative effect results are as follows:
the treatment effect of the traditional Chinese medicine is shown in table 1, and the traditional Chinese medicine composition has a better treatment effect.
TABLE 1 statistics of treatment Effect
The above description of the embodiments is only intended to illustrate the method of the invention and its core idea. It should be noted that, for those skilled in the art, without departing from the principle of the present invention, several improvements and modifications can be made to the present invention, and these improvements and modifications will also fall into the protection scope of the claims of the present invention.
Claims (8)
1. The traditional Chinese medicine composition for treating myasthenia gravis is characterized by being prepared from the following traditional Chinese medicine raw materials in parts by weight: 8-15 parts of morinda officinalis, 10-24 parts of salvia miltiorrhiza, 5-10 parts of immature bitter orange, 20-60 parts of codonopsis pilosula, 20-160 parts of astragalus membranaceus, 8-10 parts of radix bupleuri, 8-30 parts of bighead atractylodes rhizome, 8-15 parts of angelica sinensis, 8-10 parts of rhizoma cimicifugae, 3-6 parts of liquorice, 3-10 parts of pericarpium citri reticulatae, 6-15 parts of medlar, 12-30 parts of Chinese yam, 12-30 parts of endothelium corneum gigeriae galli, 6-15 parts of pawpaw and 15-30 parts of poria cocos.
2. The traditional Chinese medicine composition according to claim 1, which is prepared from the following traditional Chinese medicine raw materials in parts by weight: 12 parts of morinda officinalis, 15 parts of salvia miltiorrhiza, 7 parts of immature bitter orange, 40 parts of codonopsis pilosula, 85 parts of astragalus membranaceus, 9 parts of radix bupleuri, 20 parts of bighead atractylodes rhizome, 12 parts of angelica sinensis, 9 parts of rhizoma cimicifugae, 5 parts of liquorice, 5 parts of pericarpium citri reticulatae, 10 parts of medlar, 25 parts of Chinese yam, 25 parts of endothelium corneum gigeriae galli, 12 parts of pawpaw and 20 parts of poria cocos.
3. A pharmaceutical preparation, which is prepared from the traditional Chinese medicine composition of claim 1 or 2 and a pharmaceutically acceptable carrier, and is an oral preparation.
4. The pharmaceutical formulation of claim 3, wherein the oral formulation is selected from the group consisting of oral liquid, tablet, pill, powder, granule, capsule.
5. The method for preparing the traditional Chinese medicine composition of claim 1 or 2, which is characterized by comprising the following steps:
weighing the traditional Chinese medicine raw materials according to the prescription amount, crushing, grinding, sieving, adding water, decocting for 2 times, mixing decoction liquids to obtain a decoction liquid, concentrating, precipitating, filtering, drying to obtain an extract, and crushing into powder.
6. Use according to any one of the following:
a. use of the Chinese medicinal composition of claim 1 or 2 for the preparation of a medicament for the treatment of myasthenia gravis;
b. use of a pharmaceutical preparation according to claim 3 or 4 for the preparation of a medicament for the treatment of myasthenia gravis.
7. The use of claim 6, wherein the myasthenia gravis in a is a myasthenia gravis with poor transportation and transformation of the spleen and stomach and yellow and greasy tongue coating.
8. The use of claim 7, wherein said myasthenia gravis in b is a myasthenia gravis with poor transportation and transformation of the spleen and stomach, and a yellow and greasy tongue coating.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810769797.XA CN108524731B (en) | 2018-07-13 | 2018-07-13 | Traditional Chinese medicine composition for treating myasthenia gravis and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810769797.XA CN108524731B (en) | 2018-07-13 | 2018-07-13 | Traditional Chinese medicine composition for treating myasthenia gravis and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108524731A CN108524731A (en) | 2018-09-14 |
| CN108524731B true CN108524731B (en) | 2021-10-22 |
Family
ID=63488231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810769797.XA Active CN108524731B (en) | 2018-07-13 | 2018-07-13 | Traditional Chinese medicine composition for treating myasthenia gravis and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108524731B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104147456A (en) * | 2014-08-27 | 2014-11-19 | 中南林业科技大学 | Decoction for treating ocular myasthenia gravis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105287996A (en) * | 2015-10-30 | 2016-02-03 | 陆康 | Traditional Chinese medicine composition for treating stomach weakness and preparation method thereof |
-
2018
- 2018-07-13 CN CN201810769797.XA patent/CN108524731B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104147456A (en) * | 2014-08-27 | 2014-11-19 | 中南林业科技大学 | Decoction for treating ocular myasthenia gravis |
Non-Patent Citations (1)
| Title |
|---|
| 补中益气汤重用黄芪治疗重症肌无力25例临床观察;刘建萌;《辽宁中医杂志》;20060118;第33卷(第01期);第58页第1栏治疗方法项下,第58页第2栏倒数第3段，第58-59页体会部分最后一段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108524731A (en) | 2018-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101513437B (en) | Antifatigue Chinese pharmaceutical composition and preparation method thereof | |
| CN101940658B (en) | A Chinese medicinal composition for treating toothache, and its preparation method | |
| CN102327390B (en) | Formula for Chinese medicine for preventing and treating chemotherapeutic toxic and side reaction and preparation method for Chinese medicinal pills | |
| CN102319407A (en) | Traditional Chinese medicine for treating gastroptosis and extraction method thereof | |
| CN109010468A (en) | Antitumor Chinese and its preparation method and application based on ancient prescription Tuoli Xiaodu | |
| CN113713031A (en) | Traditional Chinese medicine composition for treating helicobacter pylori infection, preparation method and application | |
| CN108042766A (en) | A kind of Bushen Tongluo supports brain cream and preparation method thereof | |
| CN112370521A (en) | Chinese and western medicine composition for promoting blood circulation to remove blood stasis and eliminating soft and hard plaque of artery and preparation method and application thereof | |
| CN101954022B (en) | Chinese medicinal composition for treating lung cancer | |
| CN108524731B (en) | Traditional Chinese medicine composition for treating myasthenia gravis and preparation thereof | |
| CN101647901B (en) | Oral Chinese herba preparation for treating postpartum qi and blood deficiency of woman and production method thereof | |
| CN101244183B (en) | Chinese medicine composing prescription for treating children's lymphoglandulae mesentericae intumesce | |
| CN104189764A (en) | Traditional Chinese medicinal preparation for treating intervention postoperative fever | |
| CN104258359A (en) | Traditional Chinese medicine combination for curing pregnancy reaction and preparation method of preparations thereof | |
| CN100431584C (en) | Chinese medicinal formulation for caring and enlarging breast | |
| CN105362630A (en) | Climacteric syndrome treatment pharmaceutical composition and preparation method thereof | |
| CN104056017A (en) | Traditional Chinese medicine composition for treating rheumatism and preparation method thereof | |
| CN104056234A (en) | Drug for hangover and preparation method thereof | |
| CN101264208A (en) | Medicinal composition for treating stomach and intestine dysfunction and preparation thereof | |
| CN110123896B (en) | Pharmaceutical composition for adjuvant treatment of tumor and preparation method thereof | |
| CN107485665A (en) | Chinese medicine composition and its related preparations for anti-premature ovarian failure | |
| CN105878901A (en) | Traditional Chinese medicine preparation for treating skin flap necrosis after breast cancer operation and preparation method | |
| CN104162090A (en) | A kind of pharmaceutical composition and preparation method thereof | |
| CN104096094A (en) | Traditional Chinese medicine for treatment of abortion disease of pattern of dual vacuity of spleen and kidney | |
| CN105169277A (en) | Fructus gardeniae oral liquid capable of protecting liver and benefiting gallbladder and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |